Developer docs
API playgroundTry for free, no card

Search company profiles

ENTYVIO

Full company profile

uuid002qo5j

Namestring
ENTYVIO
Legal namestring
Takeda Pharmaceuticals U.S.A., Inc.
Websiteurl
entyvio.com
Company typeenum
Private
Founded yearint
2014
Descriptiontext

ENTYVIO (vedolizumab) is a prescription biologic medication approved by the FDA for the treatment of moderate to severe ulcerative colitis (UC) and Crohn's disease in adults. The active molecule is a monoclonal antibody that selectively targets the α4β7 integrin, blocking gut-homing white blood cells from entering intestinal tissue and thereby providing gut-selective anti-inflammatory activity distinct from systemic immunosuppression. The product is offered in two formulations: ENTYVIO IV (300 mg intravenous infusion administered at 0, 2, and 6 weeks, then every 8 weeks) and ENTYVIO Pen (108 mg subcutaneous self-administered injection every two weeks). The IV formulation received FDA approval in May 2014; the Pen formulation was approved for UC in 2023 and for Crohn's disease in 2024. ENTYVIO is marketed by Takeda Pharmaceuticals U.S.A., Inc., a subsidiary of the publicly listed Japanese pharmaceutical company Takeda Pharmaceutical Company Limited.

The business model is a high-value prescription biologic franchise with US list pricing of $9,359.91 per IV dose and $3,369.57 per Pen dose (as of mid-2025). Revenue is generated through specialty pharmacy distribution (Pen), infusion center and healthcare provider administration (IV), and home infusion services. The product is supported by the EntyvioConnect patient access program, which offers copay assistance up to $20,000 annually, nurse educator support, and a $0 copay option for eligible commercially insured patients, alongside the Entyvio Connections peer ambassador community. Revenue is not separately disclosed at the product level; figures are consolidated into Takeda's overall financial reporting, where ENTYVIO is positioned as a flagship growth asset within the gastrointestinal franchise.

The product has been positioned as the #1 prescribed biologic for Crohn's disease and ulcerative colitis combined, based on claims data analysis covering January 2023 through December 2025, with over 10 years of accumulated patient experience and multiple supportive clinical trials (including VISIBLE 1, VISIBLE 2, VARSITY, and VERSIFY). Distribution and patient-support infrastructure extends to the approximately 1.2 million US adults with ulcerative colitis and 1 million+ US adults with Crohn's disease, with disease-state partnerships such as the collaboration with the Crohn's & Colitis Foundation. The US marketing organization operates out of Takeda's US headquarters in Cambridge, Massachusetts.

Short descriptiontext

ENTYVIO (vedolizumab) is an FDA-approved prescription biologic marketed by Takeda Pharmaceuticals U.S.A., Inc. for treating moderate to severe ulcerative colitis and Crohn's disease in adults, offered as an IV infusion and a subcutaneous self-administered Pen.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersWooster, United States
HQ citystring
Wooster
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
biologic medications, inflammatory bowel disease, monoclonal antibody therapy, gastroenterology treatments, prescription pharmaceuticals
Industry3 codes
PRIMARYHLAAAAAA
Monoclonal Antibody Therapeutics (mAbs)
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAIAAAD
Immunology & Inflammation Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIACAE
Gastroenterology Specialty Pharmaceuticals
SIC code1 code
  • Biological Products, (No Disgnostic Substances)2836
Product category
Biologic Pharmaceuticals — Gastroenterology
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Pharmaceutical Product Sales
TypeOthers
Description

ENTYVIO (vedolizumab) is a prescription biologic medication sold to patients with moderate to severe ulcerative colitis or Crohn's disease. Revenue is generated through the sale of both the IV infusion formulation (300 mg) and the subcutaneous injection formulation (108 mg ENTYVIO Pen). Distribution occurs through healthcare provider offices, infusion centers, and specialty pharmacies. Takeda Pharmaceuticals U.S.A., Inc. is the manufacturer and marketer.

entyvio.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Supply Chain, Marketing or Sales, Personnel, Operations
Pricing details3 tiers
1ENTYVIO IV (300 mg) - List Price
ModelUnit PricingBilling cadenceMulti-year contract
Notes

List price: $9,359.91 per dose. Maintenance dose administered every 8 weeks, resulting in 6 doses per year after the first year (8 doses in first year including starter doses).

entyvio.com
2ENTYVIO Pen (108 mg) - List Price
ModelUnit PricingBilling cadenceMulti-year contract
Notes

List price: $3,369.57 per dose. Maintenance dose administered every 2 weeks, resulting in approximately 26 doses per year.

entyvio.com
3EntyvioConnect Co-Pay Program
ModelSubscriptionBilling cadenceAnnual
Notes

Eligible commercially insured patients may pay as little as $0 per dose, up to a maximum annual benefit of $20,000 per year. Not available for patients with federal or state government-funded healthcare programs (Medicare, Medicaid, TRICARE, etc.).

entyvio.com
GTM typeB2C
B2C
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 4 records shown
1EntyvioConnect
Description

Patient support program offering co-pay assistance, nurse educator support, treatment reminders, and resources for ENTYVIO patients.

entyvio.com
+3 more records
Core offering1 text field

ENTYVIO (vedolizumab) is a gut-focused biologic prescription medication for adults with moderate to severe ulcerative colitis or Crohn's disease. It is offered in two formulations: an intravenous infusion (ENTYVIO IV, 300 mg vedolizumab, dosed every 8 weeks) administered by healthcare professionals, and a self-administered subcutaneous injection (ENTYVIO Pen, 108 mg vedolizumab, dosed every 2 weeks) delivered through specialty pharmacies. The product is manufactured and marketed in the U.S. by Takeda Pharmaceuticals U.S.A., Inc.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 6 values shown
  • UC: 47% achieved response at 6 weeks (vs 26% placebo); 42% achieved remission at 1 year (vs 16% placebo)
+5 more records
Product overview1 text field

ENTYVIO (vedolizumab) is a gut-focused biologic medication available in two formulations: ENTYVIO IV (300 mg intravenous infusion) and ENTYVIO Pen (108 mg subcutaneous injection). The core products work by blocking certain inflammation-causing cells from entering the gut. All patients begin with at least 2 IV starter doses before transitioning to either IV maintenance every 8 weeks or self-injection with the ENTYVIO Pen every 2 weeks. Supporting the medication are patient programs including EntyvioConnect (financial and nurse support) and Entyvio Connections (peer mentorship).

Product and service4 records
1ENTYVIO IV (vedolizumab) 300 mg
CategoryBiologic pharmaceutical — prescription infusion
Description

Intravenous infusion formulation of vedolizumab administered by healthcare professionals at provider offices, infusion centers, or at home with medical support. Starting doses at Weeks 0, 2, and 6 followed by maintenance doses every 8 weeks. Indicated for adults with moderate to severe UC or Crohn's disease who have not responded to or could not tolerate other medicines.

2ENTYVIO Pen (vedolizumab) 108 mg
CategoryBiologic pharmaceutical — self-administered injection
Description

Self-administered subcutaneous injection pen containing 108 mg vedolizumab, for maintenance therapy after at least 2 IV starter doses. Delivered through specialty pharmacy for at-home or on-the-go use, administered every 2 weeks (up to 26 doses per year). Indicated for adults with moderate to severe UC or Crohn's disease.

3EntyvioConnect
CategoryPatient support service
Description

Patient support program accompanying the ENTYVIO prescription, providing co-pay assistance (eligible commercially insured patients may pay as little as $0 per dose, up to a $20,000 annual maximum benefit), 1-on-1 nurse educator support, treatment reminders, self-injection training kits, and insurance navigation for adults prescribed ENTYVIO.

4Entyvio Connections
CategoryPatient community / peer support program
Description

Takeda-sponsored peer support program connecting current ENTYVIO patients with Patient Ambassadors who share their treatment experiences living with moderate to severe UC or Crohn's disease.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Takeda provides funding to the Crohn's & Colitis Foundation in support of its mission to cure Crohn's disease and ulcerative colitis and improve quality of life for those affected. The Foundation sponsors research and offers educational programs for patients and healthcare professionals.

2Entyvio Connections Patient Ambassador Program
Strategic tierMinorTypeOthers
Description

Entyvio Connections is a Takeda-sponsored patient ambassador program connecting current ENTYVIO patients with Patient Ambassadors who share their treatment experiences. Registration occurs through UCCDMentorProgram.com.

entyvio.com
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Janssen markets Remicade, Stelara, Simponi, and Tremfya—a portfolio spanning multiple IBD biologic mechanisms. As one of the most diversified immunology players, Janssen is a broad incumbent whose portfolio approach competes directly with ENTYVIO across UC and Crohn's.

2Stelara (ustekinumab) - Janssen
TypeDirect peer
Description

Stelara is Janssen's IL-12/23 inhibitor approved for moderate-to-severe UC and Crohn's disease, with both IV induction and SC maintenance dosing. It competes directly with ENTYVIO across the same IBD indications with a different mechanism of action.

3Rinvoq (upadacitinib) - AbbVie
TypeDirect peer
Description

Rinvoq is AbbVie's oral JAK inhibitor approved for moderate-to-severe UC and under investigation for Crohn's disease. Its oral administration route differentiates it from injectable/infusion biologics like ENTYVIO and represents a meaningful convenience advantage.

4Cimzia (certolizumab pegol) - UCB
TypeDirect peer
Description

Cimzia is UCB's TNF-alpha inhibitor approved for Crohn's disease with a SC administration route. It competes directly with ENTYVIO in the moderate-to-severe Crohn's biologic market with a similar patient and prescriber base.

5Simponi (golimumab) - Janssen
TypeDirect peer
Description

Simponi is Janssen's TNF-alpha inhibitor approved specifically for moderate-to-severe ulcerative colitis with SC administration. It competes directly with ENTYVIO in the UC maintenance setting.

6Skyrizi (risankizumab) - AbbVie
TypeDirect peer
Description

Skyrizi is AbbVie's IL-23 inhibitor approved for Crohn's disease and UC, positioning it as a next-generation competitor to ENTYVIO. Its selective IL-23 mechanism and favorable safety profile make it a primary share-take candidate in biologic-naive IBD patients.

7Humira (adalimumab) - AbbVie
TypeDirect peer
Description

Humira is AbbVie's TNF-alpha inhibitor approved for moderate-to-severe ulcerative colitis and Crohn's disease, the same IBD indications as ENTYVIO. It was ENTYVIO's head-to-head comparator in pivotal UC trials and represents the most-established legacy biologic competitor in IBD.

8Remicade (infliximab) - Janssen
TypeDirect peer
Description

Remicade is Janssen's TNF-alpha inhibitor and one of the original biologics approved for both UC and Crohn's disease. It is administered by IV infusion in clinical settings and represents a long-standing direct competitor in the IBD biologic market.

9Zeposia (ozanimod) - Bristol Myers Squibb
TypeDirect peer
Description

Zeposia is BMS's oral S1P receptor modulator approved for moderate-to-severe ulcerative colitis. Its oral administration and novel mechanism position it as a direct emerging competitor to ENTYVIO in UC maintenance therapy.

TypeBroad incumbent
Description

AbbVie is the manufacturer of Humira, Skyrizi, and Rinvoq—multiple direct competitors to ENTYVIO across the IBD biologic landscape. As the dominant IBD competitor with the deepest commercial infrastructure, AbbVie is the most consequential broad incumbent in ENTYVIO's therapeutic area.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers6 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature2 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

ENTYVIO

Biologic Pharmaceuticals — Gastroenterologyentyvio.com

ENTYVIO (vedolizumab) is an FDA-approved prescription biologic marketed by Takeda Pharmaceuticals U.S.A., Inc. for treating moderate to severe ulcerative colitis and Crohn's disease in adults, offered as an IV infusion and a subcutaneous self-administered Pen.

What ENTYVIO does

ENTYVIO (vedolizumab) is a prescription biologic medication approved by the FDA for the treatment of moderate to severe ulcerative colitis (UC) and Crohn's disease in adults. The active molecule is a monoclonal antibody that selectively targets the α4β7 integrin, blocking gut-homing white blood cells from entering intestinal tissue and thereby providing gut-selective anti-inflammatory activity distinct from systemic immunosuppression. The product is offered in two formulations: ENTYVIO IV (300 mg intravenous infusion administered at 0, 2, and 6 weeks, then every 8 weeks) and ENTYVIO Pen (108 mg subcutaneous self-administered injection every two weeks). The IV formulation received FDA approval in May 2014; the Pen formulation was approved for UC in 2023 and for Crohn's disease in 2024. ENTYVIO is marketed by Takeda Pharmaceuticals U.S.A., Inc., a subsidiary of the publicly listed Japanese pharmaceutical company Takeda Pharmaceutical Company Limited.

The business model is a high-value prescription biologic franchise with US list pricing of $9,359.91 per IV dose and $3,369.57 per Pen dose (as of mid-2025). Revenue is generated through specialty pharmacy distribution (Pen), infusion center and healthcare provider administration (IV), and home infusion services. The product is supported by the EntyvioConnect patient access program, which offers copay assistance up to $20,000 annually, nurse educator support, and a $0 copay option for eligible commercially insured patients, alongside the Entyvio Connections peer ambassador community. Revenue is not separately disclosed at the product level; figures are consolidated into Takeda's overall financial reporting, where ENTYVIO is positioned as a flagship growth asset within the gastrointestinal franchise.

The product has been positioned as the #1 prescribed biologic for Crohn's disease and ulcerative colitis combined, based on claims data analysis covering January 2023 through December 2025, with over 10 years of accumulated patient experience and multiple supportive clinical trials (including VISIBLE 1, VISIBLE 2, VARSITY, and VERSIFY). Distribution and patient-support infrastructure extends to the approximately 1.2 million US adults with ulcerative colitis and 1 million+ US adults with Crohn's disease, with disease-state partnerships such as the collaboration with the Crohn's & Colitis Foundation. The US marketing organization operates out of Takeda's US headquarters in Cambridge, Massachusetts.

ENTYVIO firmographics

Firmographics
Name
ENTYVIO
Legal name
Takeda Pharmaceuticals U.S.A., Inc.
Website
https://entyvio.com
Company type
Private
Founded year
2014
Operating status
Operating
Headcount range
1–10 employees
Short description
ENTYVIO (vedolizumab) is an FDA-approved prescription biologic marketed by Takeda Pharmaceuticals U.S.A., Inc. for treating moderate to severe ulcerative colitis and Crohn's disease in adults, offered as an IV infusion and a subcutaneous self-administered Pen.
Ownership category
akta.pro rank

ENTYVIO industry classification

Industry
Product category
Biologic Pharmaceuticals — Gastroenterology
SIC
Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAAAAAA
Monoclonal Antibody Therapeutics (mAbs)
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAIAAAD
Immunology & Inflammation Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIACAE
Gastroenterology Specialty Pharmaceuticals

Keywords

  • Biologic medications
  • Inflammatory bowel disease
  • Monoclonal antibody therapy
  • Gastroenterology treatments
  • Prescription pharmaceuticals

Where ENTYVIO is headquartered

Location

Headquarters

HQ city
Wooster
HQ country
United States
HQ region
North America

Offices1 record

Markets served

ENTYVIO business model

Business model
GTM type
B2C
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Supply Chain, Marketing or Sales, Personnel, Operations

Revenue model

  1. Pharmaceutical Product Sales: ENTYVIO (vedolizumab) is a prescription biologic medication sold to patients with moderate to severe ulcerative colitis or Crohn's disease. Revenue is generated through the sale of both the IV infusion formulation (300 mg) and the subcutaneous injection formulation (108 mg ENTYVIO Pen). Distribution occurs through healthcare provider offices, infusion centers, and specialty pharmacies. Takeda Pharmaceuticals U.S.A., Inc. is the manufacturer and marketer.

Pricing tiers

ModelBillingPrice
Unit PricingMulti-year contractENTYVIO IV (300 mg) - List Price
Unit PricingMulti-year contractENTYVIO Pen (108 mg) - List Price
SubscriptionAnnualEntyvioConnect Co-Pay Program

Go-to-market motion1 record

Distribution channels3 records

Marketing channels5 records

ENTYVIO product offering

Product offering

Core offering

ENTYVIO (vedolizumab) is a gut-focused biologic prescription medication for adults with moderate to severe ulcerative colitis or Crohn's disease. It is offered in two formulations: an intravenous infusion (ENTYVIO IV, 300 mg vedolizumab, dosed every 8 weeks) administered by healthcare professionals, and a self-administered subcutaneous injection (ENTYVIO Pen, 108 mg vedolizumab, dosed every 2 weeks) delivered through specialty pharmacies. The product is manufactured and marketed in the U.S. by Takeda Pharmaceuticals U.S.A., Inc.

Product overview

ENTYVIO (vedolizumab) is a gut-focused biologic medication available in two formulations: ENTYVIO IV (300 mg intravenous infusion) and ENTYVIO Pen (108 mg subcutaneous injection). The core products work by blocking certain inflammation-causing cells from entering the gut. All patients begin with at least 2 IV starter doses before transitioning to either IV maintenance every 8 weeks or self-injection with the ENTYVIO Pen every 2 weeks. Supporting the medication are patient programs including EntyvioConnect (financial and nurse support) and Entyvio Connections (peer mentorship).

Differentiator

Problem solved

Functional benefit

Brands

  • EntyvioConnect: Patient support program offering co-pay assistance, nurse educator support, treatment reminders, and resources for ENTYVIO patients.
  • ENTYVIO IV
  • ENTYVIO Pen
  • Entyvio Connections

Products and services

  • ENTYVIO IV (vedolizumab) 300 mg Intravenous infusion formulation of vedolizumab administered by healthcare professionals at provider offices, infusion centers, or at home with medical support. Starting doses at Weeks 0, 2, and 6 followed by maintenance doses every 8 weeks. Indicated for adults with moderate to severe UC or Crohn's disease who have not responded to or could not tolerate other medicines.
  • ENTYVIO Pen (vedolizumab) 108 mg Self-administered subcutaneous injection pen containing 108 mg vedolizumab, for maintenance therapy after at least 2 IV starter doses. Delivered through specialty pharmacy for at-home or on-the-go use, administered every 2 weeks (up to 26 doses per year). Indicated for adults with moderate to severe UC or Crohn's disease.
  • EntyvioConnect Patient support program accompanying the ENTYVIO prescription, providing co-pay assistance (eligible commercially insured patients may pay as little as $0 per dose, up to a $20,000 annual maximum benefit), 1-on-1 nurse educator support, treatment reminders, self-injection training kits, and insurance navigation for adults prescribed ENTYVIO.
  • Entyvio Connections Takeda-sponsored peer support program connecting current ENTYVIO patients with Patient Ambassadors who share their treatment experiences living with moderate to severe UC or Crohn's disease.

Quantifiable outcome

  • UC: 47% achieved response at 6 weeks (vs 26% placebo); 42% achieved remission at 1 year (vs 16% placebo)
  • +5 more outcomes

Companies that use ENTYVIO

Customer profile

Named customers6 records

Segments2 records

Ideal customer profiles2 records

ENTYVIO technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature2 records

ENTYVIO partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered minor.

  • Crohn's & Colitis FoundationminorStrategic or Co-development PartnerTakeda provides funding to the Crohn's & Colitis Foundation in support of its mission to cure Crohn's disease and ulcerative colitis and improve quality of life for those affected. The Foundation sponsors research and offers educational programs for patients and healthcare professionals.
  • Entyvio Connections Patient Ambassador ProgramminorOthersEntyvio Connections is a Takeda-sponsored patient ambassador program connecting current ENTYVIO patients with Patient Ambassadors who share their treatment experiences. Registration occurs through UCCDMentorProgram.com.

Scale indicators5 records

Recent moves6 records

Expansion highlights4 records

ENTYVIO competitors and assessment

Company assessment

Broad incumbents

  • Janssen (Johnson & Johnson Innovative Medicine): Janssen markets Remicade, Stelara, Simponi, and Tremfya—a portfolio spanning multiple IBD biologic mechanisms. As one of the most diversified immunology players, Janssen is a broad incumbent whose portfolio approach competes directly with ENTYVIO across UC and Crohn's.
  • AbbVie: AbbVie is the manufacturer of Humira, Skyrizi, and Rinvoq—multiple direct competitors to ENTYVIO across the IBD biologic landscape. As the dominant IBD competitor with the deepest commercial infrastructure, AbbVie is the most consequential broad incumbent in ENTYVIO's therapeutic area.

Direct peers

  • Stelara (ustekinumab) - Janssen: Stelara is Janssen's IL-12/23 inhibitor approved for moderate-to-severe UC and Crohn's disease, with both IV induction and SC maintenance dosing. It competes directly with ENTYVIO across the same IBD indications with a different mechanism of action.
  • Rinvoq (upadacitinib) - AbbVie: Rinvoq is AbbVie's oral JAK inhibitor approved for moderate-to-severe UC and under investigation for Crohn's disease. Its oral administration route differentiates it from injectable/infusion biologics like ENTYVIO and represents a meaningful convenience advantage.
  • Cimzia (certolizumab pegol) - UCB: Cimzia is UCB's TNF-alpha inhibitor approved for Crohn's disease with a SC administration route. It competes directly with ENTYVIO in the moderate-to-severe Crohn's biologic market with a similar patient and prescriber base.
  • Simponi (golimumab) - Janssen: Simponi is Janssen's TNF-alpha inhibitor approved specifically for moderate-to-severe ulcerative colitis with SC administration. It competes directly with ENTYVIO in the UC maintenance setting.
  • Skyrizi (risankizumab) - AbbVie: Skyrizi is AbbVie's IL-23 inhibitor approved for Crohn's disease and UC, positioning it as a next-generation competitor to ENTYVIO. Its selective IL-23 mechanism and favorable safety profile make it a primary share-take candidate in biologic-naive IBD patients.
  • Humira (adalimumab) - AbbVie: Humira is AbbVie's TNF-alpha inhibitor approved for moderate-to-severe ulcerative colitis and Crohn's disease, the same IBD indications as ENTYVIO. It was ENTYVIO's head-to-head comparator in pivotal UC trials and represents the most-established legacy biologic competitor in IBD.
  • Remicade (infliximab) - Janssen: Remicade is Janssen's TNF-alpha inhibitor and one of the original biologics approved for both UC and Crohn's disease. It is administered by IV infusion in clinical settings and represents a long-standing direct competitor in the IBD biologic market.
  • Zeposia (ozanimod) - Bristol Myers Squibb: Zeposia is BMS's oral S1P receptor modulator approved for moderate-to-severe ulcerative colitis. Its oral administration and novel mechanism position it as a direct emerging competitor to ENTYVIO in UC maintenance therapy.

Market position

Strengths5 records

Weaknesses4 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

ENTYVIO social profiles

Digital presence

ENTYVIO financial estimates

Financial estimate

Revenue estimate

Valuation estimate

ENTYVIO leadership team

Management profile

Number of profiles

ENTYVIO subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

ENTYVIO funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

ENTYVIO M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about ENTYVIO

What does ENTYVIO do?

ENTYVIO (vedolizumab) is a gut-focused biologic prescription medication for adults with moderate to severe ulcerative colitis or Crohn's disease. It is offered in two formulations: an intravenous infusion (ENTYVIO IV, 300 mg vedolizumab, dosed every 8 weeks) administered by healthcare professionals, and a self-administered subcutaneous injection (ENTYVIO Pen, 108 mg vedolizumab, dosed every 2 weeks) delivered through specialty pharmacies. The product is manufactured and marketed in the U.S. by Takeda Pharmaceuticals U.S.A., Inc.

Is ENTYVIO a public or private company?

ENTYVIO is a private company. It is classified as corporate owned and is currently operating.

When was ENTYVIO founded?

ENTYVIO was founded in 2014. It employs 1 to 10 people.

Where is ENTYVIO based?

ENTYVIO is headquartered in Wooster, United States, in the North America region.

How does ENTYVIO make money?

One revenue line is on record: pharmaceutical Product Sales.

Who are ENTYVIO's main competitors?

Broad incumbents on record are Janssen (Johnson & Johnson Innovative Medicine) and AbbVie. Direct peers are Stelara (ustekinumab) - Janssen, Rinvoq (upadacitinib) - AbbVie, Cimzia (certolizumab pegol) - UCB, Simponi (golimumab) - Janssen, Skyrizi (risankizumab) - AbbVie, Humira (adalimumab) - AbbVie, Remicade (infliximab) - Janssen and Zeposia (ozanimod) - Bristol Myers Squibb.

Does ENTYVIO have an API?

No public API is recorded for ENTYVIO.

What industry is ENTYVIO in?

ENTYVIO's product category is Biologic Pharmaceuticals — Gastroenterology. Its primary akta.pro industry code is HLAAAAAA, Monoclonal Antibody Therapeutics (mAbs), with a secondary code of HLAIAAAD, Immunology & Inflammation Pharmaceuticals. Its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals